Basic Science Ovarian Cancer Solitomab, an EpCAM/CD3 bispecific antibody (BITE), is highly active against primary chemotherapy resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo

被引：0
|
作者：
English, Diana P. [1 ]
Bellone, Stefania [1 ]
Schwab, Carlton L. [1 ]
Roque, Dana M. [1 ]
Chatterjee, Sudeshna [1 ]
Ratner, Elena [1 ]
Schwartz, Peter E. [1 ]
Rutherford, Thomas J. [1 ]
Santin, Alessandro D. [1 ]
机构：
[1] Yale Univ, Dept Obstet & Gynecol, New Haven, CT 06520 USA
来源：
GYNECOLOGIC ONCOLOGY | 2015年 / 136卷 / 02期
关键词：
D O I：
10.1016/j.ygyno.2014.11.041
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：401 / 401
页数：1
相关论文
共 7 条
  • [1] Solitomab, an Epithelial Cell Adhesion Molecule/CD3 Bispecific Antibody (BiTE), Is Highly Active Against Primary Chemotherapy-Resistant Ovarian Cancer Cell Lines In Vitro and Fresh Tumor Cells Ex Vivo
    English, Diana P.
    Bellone, Stefania
    Schwab, Carlton L.
    Roque, Dana M.
    Lopez, Salvatore
    Bortolomai, Ileana
    Cocco, Emiliano
    Bonazzoli, Elena
    Chatterjee, Sudeshna
    Ratner, Elena
    Silasi, Dan-Arin
    Azodi, Masoud
    Schwartz, Peter E.
    Rutherford, Thomas J.
    Santin, Alessandro D.
    CANCER, 2015, 121 (03) : 403 - 412
  • [2] Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro
    Ferrari, Francesca
    Bellone, Stefania
    Black, Jonathan
    Schwab, Carlton L.
    Lopez, Salvatore
    Cocco, Emiliano
    Bonazzoli, Elena
    Predolini, Federica
    Menderes, Gulden
    Litkouhi, Babak
    Ratner, Elena
    Silasi, Dan-Arin
    Azodi, Masoud
    Schwartz, Peter E.
    Santin, Alessandro D.
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2015, 34
  • [3] Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro
    Francesca Ferrari
    Stefania Bellone
    Jonathan Black
    Carlton L. Schwab
    Salvatore Lopez
    Emiliano Cocco
    Elena Bonazzoli
    Federica Predolini
    Gulden Menderes
    Babak Litkouhi
    Elena Ratner
    Dan-Arin Silasi
    Masoud Azodi
    Peter E. Schwartz
    Alessandro D. Santin
    Journal of Experimental & Clinical Cancer Research, 34
  • [4] Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro
    Bellone, Stefania
    Black, Jonathan
    English, Diana P.
    Schwab, Carlton L.
    Lopez, Salvatore
    Cocco, Emiliano
    Bonazzoli, Elena
    Predolini, Federica
    Ferrari, Francesca
    Ratner, Elena
    Silasi, Dan-Arin
    Azodi, Masoud
    Schwartz, Peter E.
    Santin, Alessandro D.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2016, 214 (01) : 99.e1 - 99.e8
  • [5] A CD3 x FRα T-cell engaging bispecific antibody for efficient killing of ovarian cancer cells with minimal cytokine release.
    Buelow, Ben
    Avanzino, Brian
    Balasubramani, Aarti
    Boudreau, Andrew
    Davison, Laura
    Ganesan, Priya
    Harris, Katherine
    Hartstein, Sharon
    Malik-Chaudhry, Harbani
    Pham, Duy
    Prabhakar, Kirthana
    Rangaswamy, Udaya
    Saiganesh, Sowmya
    Schellenberger, Ute
    Ugamraj, Harshad
    Kehm, Hannes
    Trinklein, Nathan
    Iyer, Suhasini
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an Ep-CAM-/CD3-bispecific antibody
    Wimberger, P
    Xiang, W
    Mayr, D
    Diebold, J
    Dreier, T
    Baeuerle, PA
    Kimmig, R
    INTERNATIONAL JOURNAL OF CANCER, 2003, 105 (02) : 241 - 248
  • [7] Anti-CD3 x anti-EGFR bispecific antibody armed T cells (EGFR BATs) kills resistant pancreatic cancer cell lines and increases sensitivity to chemotherapy
    Lum, Lawrence G.
    Ung, Johnson
    Thakur, Archana
    CANCER RESEARCH, 2019, 79 (13)
1